{"doc_id": "33875266", "type of study": "Therapy", "title": "", "abstract": "The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59\u00a0years: A phase I randomized, double-blinded, controlled trial.\nThis study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine.\nIn a phase I randomized, double-blinded, placebo-controlled trial involving 192 healthy adults 18-59\u00a0years old, two injections of three doses (50 EU, 100 EU, 150 EU) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2- or 4-week interval.\nThe safety and immunogenicity of the vaccine were evaluated.\nVaccination was completed in 191 subjects.\nForty-four adverse reactions occurred within 28\u00a0days, most commonly mild pain and redness at the injection site or slight fatigue.\nAt days 14 and 28, the seroconversion rates were 87.5% and 79.2% (50 EU), 100% and 95.8% (100 EU), and 95.8% and 87.5% (150 EU), respectively, with geometric mean titers (GMTs) of 18.1 and 10.6, 54.5 and 15.4, and 37.1 and 18.5, respectively, for the schedules with 2-week and 4-week intervals.\nSeroconversion was associated with synchronous upregulation of antibodies against the S protein, N protein and virion and a cytotoxic T lymphocyte (CTL) response.\nNo cytokines and immune cells related to immunopathology were observed.\nTranscriptome analysis revealed the genetic diversity of immune responses induced by the vaccine.\nIn a population aged 18-59\u00a0years in this trial, this inactivated SARS-CoV-2 vaccine was safe and immunogenic.\nTRIAL REGISTRATION : CTR20200943 and NCT04412538.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 89}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years : A phase I randomized , double-blinded , controlled trial .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "inactivated SARS-CoV-2 vaccine", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 66, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 23, "end": 30, "has_count": ["2"]}], "has_activity": [{"text": "inactivated", "maps_to": "C5206843:Inactivated", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 10}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 29}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "This study examined the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "inactivated SARS-CoV-2 vaccine", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 86, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 23, "end": 30, "has_count": ["2"]}], "has_activity": [{"text": "inactivated", "maps_to": "C5206843:Inactivated", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 30}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 49}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHOD", "Text": "In a phase I randomized , double-blinded , placebo-controlled trial involving 192 healthy adults 18-59 years old , two injections of three doses ( 50 EU , 100 EU , 150 EU ) of an inactivated SARS-CoV-2 vaccine or placebo were administered intramuscularly at a 2- or 4-week interval .", "Evidence Elements": {"Participant": [{"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 89}], "Intervention": [{"term": "doses", "negation": "affirmed", "UMLS": {}, "start": 139, "end": 144, "has_relation": "N/A"}, {"term": "inactivated SARS-CoV-2 vaccine", "negation": "affirmed", "UMLS": {}, "start": 179, "end": 209, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 23, "end": 30, "has_count": ["2"]}], "has_activity": [{"text": "inactivated", "maps_to": "C5206843:Inactivated", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 50, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHOD", "Text": "The safety and immunogenicity of the vaccine were evaluated .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 44, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 10}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 15, "end": 29}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Vaccination was completed in 191 subjects .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Forty-four adverse reactions occurred within 28 days , most commonly mild pain and redness at the injection site or slight fatigue .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 28}, {"term": "mild pain", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 78}, {"term": "redness at the injection site", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 112}, {"term": "slight", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 122}], "Observation": [], "Count": [{"term": "Forty-four", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "At days 14 and 28 , the seroconversion rates were 87.5 % and 79.2 % ( 50 EU ) , 100 % and 95.8 % ( 100 EU ) , and 95.8 % and 87.5 % ( 150 EU ) , respectively , with geometric mean titers ( GMTs ) of 18.1 and 10.6 , 54.5 and 15.4 , and 37.1 and 18.5 , respectively , for the schedules with 2-week and 4-week intervals .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "seroconversion rates", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 44}, {"term": "geometric mean titers ( GMTs )", "negation": "affirmed", "UMLS": {}, "start": 165, "end": 195}], "Observation": [{"term": "87.5 %", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 56}, {"term": "79.2 % ( 50 EU )", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 77}, {"term": "100 %", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 85}, {"term": "95.8 % ( 100 EU )", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 107}, {"term": "95.8 %", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 96}, {"term": "87.5 % ( 150 EU )", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 142}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Seroconversion was associated with synchronous upregulation of antibodies against the S protein , N protein and virion and a cytotoxic T lymphocyte ( CTL ) response .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Seroconversion", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14, "has_relation": "N/A"}], "Outcome": [{"term": "cytotoxic T lymphocyte (", "negation": "affirmed", "UMLS": {}, "start": 125, "end": 149}], "Observation": [{"term": "synchronous upregulation of antibodies against the S protein , N protein and virion", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 118}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "No cytokines and immune cells related to immunopathology were observed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "cytokines", "negation": "negated", "UMLS": {}, "start": 3, "end": 12}, {"term": "immune cells related to immunopathology", "negation": "negated", "UMLS": {}, "start": 17, "end": 56}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Transcriptome analysis revealed the genetic diversity of immune responses induced by the vaccine .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 96, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "genetic diversity of immune responses", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 73}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "In a population aged 18-59 years in this trial , this inactivated SARS-CoV-2 vaccine was safe and immunogenic .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "inactivated SARS-CoV-2 vaccine", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 84, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 23, "end": 30, "has_count": ["2"]}], "has_activity": [{"text": "inactivated", "maps_to": "C5206843:Inactivated", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 93}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : CTR20200943 and NCT04412538 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "CTR20200943", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 32, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}